• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Stromedix

edit

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

Milestones

edit

• 
  Stromedix added Dan Lynch as Executive Chairman.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Shelia Violette as Vice President, Research.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Brad Maroni as Chief Medical Officer.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Michael Gilman as Founder and CEO.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix received $2M in Series C funding. (1/26/11)
  Posted 1/26/11 at 7:03pm via masshightech.com
• 
  Stromedix received $1M in Series A funding. (3/22/07)
  Posted 3/19/10 at 11:40pm
• 
  Stromedix received $25M in Series B funding. (4/21/08)
  Posted 6/3/09 at 10:22pm
• 
  Stromedix — has taken in $2 million of a planned $15.5 million new financing round (1/26/11)
  Posted 1/26/11 at 6:29am via masshightech.com

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/4/09

Sources

1. Cap Funding Report [edit]
2. Capital Funding Report [edit]
3. Stromedix lands $2M, looks for $15.5M in new funding (masshightech.com) [edit]
4. Stromedix lands $2M, looks for $15.5M in new funding (masshightech.com) [edit]